A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Walter P WodchisDoug CoyleJeffrey S HochLisa VandermeerSasha MazzarelloZhou WangGeorge DranitsarisDean FergussonMark Clemons

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2017)

The risk-guided antiemetic prophylaxis is an economically attractive option for patients receiving chemotherapy for early-stage breast cancer. This information supports the implementation of risk prediction models to guide chemotherapy-induced nausea and vomiting prophylaxis in clinical practices.

Keyphrases

chemotherapy induced
early stage
primary care
healthcare
emergency department
sentinel lymph node
breast cancer risk
radiation therapy
young adults
health information
social media